Literature DB >> 8679789

Plasma homovanillic acid concentrations in catatonia.

G Northoff1, L Demisch, J Wenke, B Pflug.   

Abstract

We investigated the dopamine metabolite plasma homovanillic acid (plasma HVA) levels in 37 catatonic patients on the day of admission before initial medication as well as in 17 healthy controls. In a prospective study catatonic syndrome was diagnosed according to criteria of Lohr and Wiesniwski (1987) and Rosebush et al (1990) whereas comorbid diagnosis was made by Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, revised (DSM III/R) (APA 1987). On the day of admission blood samples were taken before initial medication. Compared to controls (80.1 +/- 40.1 pmol/mliter) catatonic patients showed significantly (P = 0.0286) increased plasma HVA (140.9 +/- 53.6 pmol/mliter). Catatonic patients free of neuroleptic medication (n = 21) differed significantly (p = 0.0416) from controls whereas neuroleptically treated catatonics (n = 16) did not. Our findings of increased plasma HVA in catatonia are explained by an alteration in either mesolimbic or mesocortical dopaminergic function, as is assumed in the case of schizophrenia. As an alternative, it may be due to increased nigrostriatal function, which can lead, as shown in animal experiments with the dopamine agonist amphetamine, to hypokinetic states resembling catatonia in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8679789     DOI: 10.1016/0006-3223(95)00184-0

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  4 in total

1.  Going Back to Kahlbaum's Psychomotor (and GABAergic) Origins: Is Catatonia More Than Just a Motor and Dopaminergic Syndrome?

Authors:  Dusan Hirjak; Katharina M Kubera; R Christian Wolf; Georg Northoff
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

2.  Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine.

Authors:  G Northoff; J Eckert; J Fritze
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

Review 3.  Systematic review of catatonia treatment.

Authors:  Anne Cm Pelzer; Frank Mma van der Heijden; Erik den Boer
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-17       Impact factor: 2.570

4.  Increased biogenic catecholamine and metabolite levels in two patients with malignant catatonia.

Authors:  Koichi Nisijima
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-12       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.